# Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

> **NCT05263609** · PHASE2 · WITHDRAWN · sponsor: **University of Oklahoma**

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05263609
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left University
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263609, "Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05263609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*